The only clinically relevant polymorphism in PACSIN2 is rs2413739, which had previously only been associated with 6-MP-related gastrointestinal toxicity in ALL patients during consolidation therapy12. This evidence concerns the gene PACSIN2 and acute lymphoblastic leukemia.